These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3001292)

  • 1. In vivo dephosphorylation of WR-2721 monitored by 31P NMR spectroscopy.
    Knizner SA; Jacobs AJ; Lyon RC; Swenberg CE
    J Pharmacol Exp Ther; 1986 Jan; 236(1):37-40. PubMed ID: 3001292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Yuhas JM
    Cancer Res; 1980 May; 40(5):1519-24. PubMed ID: 6245795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721).
    Thompson DC; Wyrick SD; Holbrook DJ; Chaney SG
    Biochem Pharmacol; 1995 Oct; 50(9):1413-9. PubMed ID: 7503792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689).
    Rasey JS; Krohn KA; Grunbaum Z; Spence AM; Menard TW; Wade RA
    Radiat Res; 1986 Jun; 106(3):366-79. PubMed ID: 3012625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Milas L; Hunter N; Stephens LC; Peters LJ
    Cancer Res; 1984 Dec; 44(12 Pt 1):5567-9. PubMed ID: 6093999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
    Milas L; McBride WH; Hunter N; Ito H
    Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of delayed-type hypersensitivity to oxazolone in whole-body-irradiated mice and protection by WR-2721.
    Srinivasan V; Weiss JF
    Radiat Res; 1984 Jun; 98(3):438-44. PubMed ID: 6328568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
    Milas L; Ito H; Hunter N
    Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrolysis of S-2-(3-aminopropylamino)ethylphosphorothioate (WR-2721).
    Risley JM; Van Etten RL; Shaw LM; Bonner H
    Biochem Pharmacol; 1986 May; 35(9):1453-8. PubMed ID: 3011018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM; Spellman JM; Culo F
    Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
    Milas L; Hunter N; Reid BO; Thames HD
    Cancer Res; 1982 May; 42(5):1888-97. PubMed ID: 6279288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
    Rasey JS; Krohn KA; Magee S; Nelson N; Chin L
    Radiat Res; 1986 Nov; 108(2):167-75. PubMed ID: 3024202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral toxicity and efficacy of WR-2721 as a radioprotectant.
    Bogo V; Jacobs AJ; Weiss JF
    Radiat Res; 1985 Nov; 104(2 Pt 1):182-90. PubMed ID: 3001816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in normal tissue responsiveness to WR-2721.
    Yuhas JM; Afzal SM; Afzal V
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1537-9. PubMed ID: 6090357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721.
    Weiss JF; Hoover RL; Kumar KS
    Free Radic Res Commun; 1987; 3(1-5):33-8. PubMed ID: 2854528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
    Utley JF; Marlowe C; Waddell WJ
    Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
    [No Abstract]   [Full Text] [Related]  

  • 17. Determination of the radioprotective effects of topical applications of MEA, WR-2721, and N-acetylcysteine on murine skin.
    Verhey LJ; Sedlacek R
    Radiat Res; 1983 Jan; 93(1):175-83. PubMed ID: 6296910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver regeneration after partial hepatectomy in the rat. Sequential events monitored by 31P-nuclear magnetic resonance spectroscopy and biochemical studies.
    Farghali H; Rilo H; Zhang W; Simplaceanu V; Gavaler JS; Ho C; van Thiel DH
    Lab Invest; 1994 Mar; 70(3):418-25. PubMed ID: 8145535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specificity of ethanol-induced dephosphorylation of rat hepatocyte keratins 8 and 18: A 31P NMR study.
    Eckert BS; Yeagle PL
    Cell Motil Cytoskeleton; 1996; 33(1):30-7. PubMed ID: 8824732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.